Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STUDY OF THE EFFECTS OF L. CASEI DG® (ENTEROLACTIS BABY) IN HEALTHY PRETERM AND FULL-TERM INFANTS. RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL.

NCT07882537 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.

NCT NCT07882537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07882537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STUDY OF THE EFFECTS OF L. CASEI DG® (ENTEROLACTIS BABY) IN HEALTHY PRETERM AND FULL-TERM INFANTS. RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL.
Lead sponsor
Alfasigma S.p.A.
Phase
Not applicable
Overall status
Completed
Start date
November 2, 2018
Completion date
June 9, 2020
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gut microbiota modulation